Welcome to our dedicated page for ACADIA Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on ACADIA Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Established with a commitment to scientific excellence and leadership in CNS research, Acadia's proprietary drug discovery platform has enabled the creation of a robust portfolio targeting conditions such as Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and schizophrenia.
Acadia's pivotal achievements include the development and commercialization of NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, the first and only FDA-approved drug for the treatment of Rett syndrome. The company's clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Situated in San Diego, one of the largest biotechnology hubs in the United States, Acadia benefits from proximity to over 400 companies and renowned research institutions like the Salk Institute for Biological Studies. This strategic location supports Acadia's mission to bring groundbreaking therapies to patients in need.
Financially, Acadia has shown significant growth, with total revenues reaching $205.8 million for the first quarter of 2024, reflecting a 74% year-over-year increase, largely due to the strong market performance of NUPLAZID and the addition of DAYBUE. The company continues to invest in its pipeline and commercial operations, maintaining a solid cash position with $470.5 million in cash, cash equivalents, and investment securities as of March 31, 2024.
Recent highlights include participation in major healthcare conferences, strategic appointments to enhance leadership in research and development, and ongoing efforts to expand the reach of DAYBUE beyond the U.S. market. Acadia’s unwavering dedication to advancing neuroscience and improving patient outcomes underscores its long-term growth potential and commitment to innovation in the biopharmaceutical landscape.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced it will report its second quarter financial results on August 6, 2024, post market close. The management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results and operations. The call will be accessible via Acadia's website under the investors section and archived until September 6, 2024. Participants can register online to receive a dial-in number and unique PIN for the call. Acadia Pharmaceuticals specializes in developing treatments for neuropsychiatric conditions and has FDA-approved drugs for Parkinson’s disease psychosis and Rett syndrome. The company is also conducting clinical-stage research on Prader-Willi syndrome and Alzheimer’s disease psychosis.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has published results from two open-label extension studies, LILAC-1™ and LILAC-2™, evaluating the long-term safety and efficacy of DAYBUE™ (trofinetide) in patients with Rett syndrome. The studies showed continued improvements in RSBQ and CGI-I scores with long-term DAYBUE treatment. LILAC-1 was a 40-week extension of the 12-week Phase 3 LAVENDER™ trial, while LILAC-2 was a 32-month study. Both studies demonstrated a safety profile consistent with the LAVENDER trial, with diarrhea and vomiting as the most common side effects. These findings contribute to a growing body of research on DAYBUE's potential ongoing impact for Rett syndrome patients, with some patients being on treatment for over two years.
Acadia Pharmaceuticals shared interim data from the LOTUS study on DAYBUE™ (trofinetide) at the 2024 IRSF Annual Scientific Meeting. The open-label study, involving 101 Rett syndrome patients, indicated that over two-thirds reported improvements in symptoms within the first month. Key areas of improvement included nonverbal communication, alertness, and social interaction. However, gastrointestinal issues like diarrhea were common, necessitating management strategies. Six-month data indicated consistent improvements but were by missing data and the lack of a placebo group. The study aims to enroll participants for at least 12 months, with the option to extend for another year. Additional findings and encore data from other studies on DAYBUE were also presented.
Acadia Pharmaceuticals announced that on May 15, 2024, its Compensation Committee granted inducement awards under the 2023 Inducement Plan. The awards include non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units (RSUs) to twenty-two new employees. The stock options have an exercise price of $15.12 per share, Acadia's closing trading price on the grant date, and will vest over four years. The RSUs will also vest over four years, with specific vesting schedules. These awards were granted as an inducement material in line with Nasdaq Listing Rule 5635(c)(4).
Acadia Pharmaceuticals has launched a 10-part documentary series, 'Magnolia’s Guide to Adventuring,' featuring the adapted adventures of families dealing with Rett syndrome. Created by award-winning TV producer AJ Tesler and his wife Jenny, the series stars their 13-year-old daughter, Magnolia. The series aims to raise awareness and redefine perceptions of Rett syndrome by showcasing activities like skiing, ice skating, and horseback riding. Episodes will be available on the Rett Revealed website. The series underscores the resilience and capabilities of those living with Rett syndrome.
Acadia Pharmaceuticals (ACAD) announced its participation in three upcoming investor conferences in May 2024, aiming to engage with the investment community. The company will host fireside chats at each conference, providing insights into its innovative work in neuroscience. Acadia has a strong track record with FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome, while also focusing on developing treatments for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric disorders.
Acadia Pharmaceuticals reported strong financial results for the first quarter of 2024, with net product sales reaching $205.8 million, a 74% year-over-year revenue growth. The increase was primarily driven by the addition of DAYBUE for Rett syndrome treatment and growth in NUPLAZID market share for Parkinson's disease psychosis. The company is focusing on expanding DAYBUE globally, advancing late-stage trials, and supporting its pipeline and business development opportunities. Acadia also presented positive clinical trial results and appointed a new executive to lead Research and Development.
Acadia Pharmaceuticals announced the winners of the first Rett Sibling Scholarship, awarding 10 academic scholarships to siblings of Rett syndrome patients. Each recipient will receive $5,000 for higher education. The program aims to support siblings' academic goals and recognize their contributions. Recipients from various states plan to study psychology, finance, and medicine. The scholarship is independently administered by ISTS. Acadia's commitment to the Rett syndrome community is highlighted through this initiative.
FAQ
What does Acadia Pharmaceuticals Inc. specialize in?
Where is Acadia Pharmaceuticals headquartered?
What are some of Acadia's key products?
What recent financial performance did Acadia report?
What are Acadia's current research focuses?
What recent achievements has Acadia Pharmaceuticals announced?
How does Acadia support the Rett syndrome community?
What is the significance of Acadia's location in San Diego?
How has Acadia's product portfolio grown recently?
What is Acadia’s approach to drug discovery?
